Table of Contents
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the obesity market
- Related current reports
- Related future reports
Obesity market potential
- Key findings
- Definition
- Patient segmentation
- Epidemiology
- Current treatment options
- Collective obesity management
- Pharmacological interventions as components of personalized programs
- Unmet need in obesity
- Safety
- Efficacy
- Compliance
Current Market overview
- Seven major market current and future market overview
- Impact of recent launches has been short-lived
- Imminent slowdown cannot be blamed on generics
- US remains core market, Europe sees greatest fluctuations, and Japan
revenues are negligible
- Environmental factors in the obesity market
- Obesity products go over-the-counter
- Is late-stage and post-marketing trial design due for an overhaul?
- Defining acceptable risk means demonstrating acceptable gain
- Increasing patient potential works against expensive interventions
- US current and future market assessment
- Japan current and future market assessment
- Five major European markets current and future market assessment
- France
- Germany
- Italy
- Spain
- UK
Brand Dynamics
- Overview of competitive landscape
- Drivers of brand choice
- Trends in marketing strategy: Xenical and Alli
- Product
- Pricing
- Placement
- Promotion
- Xenical (orlistat, Roche)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Alli (orlistat, GlaxoSmithKline)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Reductil/Meridia (sibutramine, Abbott)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Sanorex/Teronac (mazindol, Sandoz)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Acomplia/Zimulti (rimonabant, Sanofi-Aventis)
- Drug profile
- Product positioning
- Brand forecast to 2018
R&D Approach
- Key findings
- Clinical trial design in obesity
- Safety
- Efficacy, endpoints and outcomes
- Comparators
- Future direction
Pipeline Analysis & Forecasts
- Key findings
- Overview
- Pipeline summary
- Comparative forecasts
- Comparator tool comparisons
- Clinical factors
- Commercial factors
- Contrave (bupropion and naltrexone, Orexigen)
- Drug profile
- Drug overview
- SWOT analysis
- Clinical trial data
- Forecasts to 2018
- Qnexa (phentermine and topiramate, Vivus Inc.)
- Drug profile
- Drug overview
- SWOT analysis
- Clinical trial data
- Forecasts to 2018
- Lorcaserin (Arena Pharmaceuticals)
- Drug profile
- Drug overview
- SWOT analysis
- Clinical trial data
- Forecasts to 2018
- Cetilistat, Alizyme Plc
- Drug profile
- Drug overview
- SWOT analysis
- Clinical trial data
- Forecasts to 2018
- Other drugs
BIBLIOGRAPHY
- Journal papers
- Presentations
- Website information
- Reports
- Books
- Datamonitor reports
APPENDIX A - MARKET ASSUMPTIONS
APPENDIX B
- Contributing experts
- Report methodology
TABLES
- Table: World Health Organization classification of obesity
- Table: Projected and forecast adult obesity prevalence (million) in the
seven major markets, 2008 - 2018
- Table: Projected and forecast adult obesity prevalence rate in the seven
major markets, 2008 - 2018
- Table: Predicted UK prevalence of childhood obesity by gender, 2004 - 2050
- Table: Summary of selected guidelines for obesity interventions, 2009
- Table: Examples of obesity-associated co-morbidities
- Table: Historical and forecast obesity market performance in the seven
major markets by volume and value, 2008 - 2018
- Table: Historical and forecast obesity market performance by region in the
seven major markets, 2008 - 2018
- Table: Sales and growth of drug classes and/or brands for obesity in the
seven major markets, 2008 - 2018
- Table: Sales forecasts for obesity in the seven major markets ($m), 2008 -
2018
- Table: Summary of opportunities and threats for the obesity market, 2009
- Table: Expected remaining lifetime healthcare costs - obese, healthy
living and smoking adults, 2009
- Table: Sales forecasts for obesity in the US ($m), 2008 - 2018
- Table: Sales forecasts for obesity in Japan ($m), 2008 - 2018
- Table: Historical and forecast obesity market performance in the five
major European markets by country and value, , 2008 - 2018
- Table: Historical and forecast obesity market share (%) in the five major
European markets by value, 2004, 2008 and 2018
- Table: Obesity prevalence versus volume and value sales across the five
major European markets, 2008
- Table: Sales forecasts ($m) for obesity in the five major European
markets, 2008 - 2018
- Table: Sales forecasts for obesity in France ($m), 2008 - 2018
- Table: Sales forecasts for obesity in Germany ($m), 2008 - 2018
- Table: Sales forecasts for obesity in Italy ($m), 2008 - 2018
- Table: Sales forecasts for obesity in Spain($m), 2008 - 2018
- Table: Specific advice on obesity drug use, National Institute for Health
& Clinical Evidence Quick Reference Guide for the National Health Service
- Table: Sales forecasts for obesity in the UK ($m), 2008 - 2018
- Table: Key branded drugs indicated for obesity, 2009
- Table: Brand dynamics of key marketed drugs for the treatment of obesity
in the seven major markets, 2008 - 2018
- Table: US formulary status for key brands for the treatment of obesity,
2009
- Table: Contraindications, cautions, adverse reactions and drug
interactions - orlistat, sibutramine and phentermine
- Table: Xenical (orlistat) - drug profile, 2009
- Table: Xenical (orlistat) - SWOT analysis, 2009
- Table: Forecast sales performance for Xenical in the seven major markets,
2008 - 2018
- Table: Alli (orlistat) - drug profile, 2009
- Table: Alli (orlistat) - SWOT analysis, 2009
- Table: Alli (orlistat) sales performance in the seven major markets, 2008
- 2018
- Table: Reductil (sibutramine) - drug profile, 2009
- Table: Reductil (sibutramine) - SWOT analysis, 2009
- Table: Acomplia/Reductil (sibutramine) sales performance in the seven
major markets, 2008 - 2018
- Table: Sanorex (mazindol) - drug profile, 2009
- Table: Sanorex (mazindol) - SWOT analysis, 2009
- Table: Sanorex/Teronac (mazindol) sales performance in the seven major
markets, 2008 - 2018
- Table: Acomplia (rimonabant) - drug profile, 2009
- Table: Acomplia/Zimulti (rimonabant) sales performance in the seven major
markets, 2008 - 2018
- Table: Late-stage pipeline summary for obesity, 2009
- Table: Obesity pipeline product performance against generic and currently
marketed products in the seven major markets, 2008 - 2018
- Table: Contrave (bupropion and naltrexone) - drug profile, 2009
- Table: Contrave (bupropion and naltrexone) SWOT analysis, 2009
- Table: Forecast sales for Contrave (bupropion and naltrexone) in the seven
major markets, 2008 - 2018
- Table: Qnexa (phentermine and topiramate) - drug profile, 2009
- Table: Qnexa (phentermine and topiramate) SWOT analysis, 2009
- Table: Forecast sales for Qnexa (phentermine and topiramate) in the seven
major markets , 2008 - 2018
- Table: Lorcaserin - drug profile, 2009
- Table: Lorcaserin SWOT analysis, 2009
- Table: Forecast sales for lorcaserin in the seven major markets, 2008 -
2018
- Table: Cetilistat - drug profile, 2009
- Table: Cetilistat SWOT analysis, 2009
- Table: Forecast sales for cetilistat in the seven major markets,, 2008 -
2018
- Table: Obesity pipeline by phase of development and activity status, 2006
- 09
- Table: Phase II obesity pipeline overview, 2009
- Table: Average trial durations used for Datamonitor forecasts of obesity
market launch dates
- Table: Review periods for new approvals in months
- Table: Forecast launch dates for late stage obesity products
- Table: Generic share, generic pricing and branded price upon generic
incursion in the cardiovascular market
- Table: Key patent expiry dates for market exclusivity for currently
marketed obesity products
FIGURES
- Figure: Definition of body mass index
- Figure: Principal drivers for obesity
- Figure: Projected and forecast adult obesity prevalence (million) ) in the
seven major markets, 2008 - 2018
- Figure: Projected and forecast adult obesity prevalence rate in the seven
major markets, 2008 - 2018
- Figure: Critical opportunities for intervention during an individual' s
life course
- Figure: Examples of child-focused interventions to target obesity
- Figure: Generic treatment pathway for obesity
- Figure: Long-term weight loss improvements with long-term maintenance
therapy
- Figure: Historic events in the obesity market, 1930 - 2009
- Figure: Forecast events in the obesity market, 2010 - 2018
- Figure: Historical and forecast obesity market performance in the seven
major markets by volume and value 2004 - 2018
- Figure: Historical and forecast seven major market obesity market
performance by volume and value by region, 2004 - 2018f
- Figure: Historical and forecast obesity market performance in the seven
major market by volume and value of key brands versus new launches and
generics, 2004 - 2018f
- Figure: Impact of over-the-counter orlistat on the US obesity market, 2004
- 08
- Figure: Historical and forecast obesity market in the US performance by
volume and value, 2004 - 2018
- Figure: Historical and forecast obesity market performance in Japan by
volume and value, 2004 - 2018
- Figure: Historical and forecast obesity market performance in the five
major European markets by volume and value, 2004 - 2018
- Figure: Historical and forecast obesity market performance in the five
major European markets by country and value,2004 - 2018
- Figure: Historical and forecast obesity market performance in France by
volume and value, 2004 - 2018
- Figure: Marketed obesity brand performance in France against generic and
pipeline products, 2004 - 2018
- Figure: Pipeline product performance in France against generic and
currently marketed products, 2004 - 2018
- Figure: Historical and forecast obesity market performance in Germany by
volume and value, 2004 - 2018
- Figure: Marketed obesity brand performance in Germany against generic and
pipeline products, 2004 - 2018
- Figure: Pipeline product performance in Germany against generic and
currently marketed products, Germany, 2004 - 2018
- Figure: Historical and forecast obesity market performance in Italy by
volume and value, 2004 - 2018
- Figure: Marketed obesity brand performance in Italy against generic and
pipeline products, 2004 - 2018
- Figure: Pipeline product performance in Italy against generic and
currently marketed products, 2004 - 2018
- Figure: Historical and forecast obesity market performance in Spain by
volume and value, 2004 - 2018
- Figure: Marketed product performance in Spain against generic and pipeline
products, 2004 - 2018
- Figure: Pipeline product performance in Spain against generic and
currently marketed products, 2004 - 2018
- Figure: Historical and forecast obesity market performance in the UK by
volume and value, 2004 - 2018
- Figure: Marketed product performance in the UK against generic and
pipeline products, 2004 - 2018
- Figure: Pipeline product performance in the UK against generic and
currently marketed products,2004 - 2018
- Figure: Brand dynamics of key marketed drugs for the treatment of obesity
in the seven major markets, 2004 - 2018
- Figure: Historic and forecast sales for Xenical (orlistat) in the seven
major markets, 2004 - 2018
- Figure: Historic and forecast sales for Alli (orlistat) in the seven major
markets, 2004 - 2018
- Figure: Historic and forecast sales for Reductil (sibutramine) in the
seven major markets, 2004 - 2018
- Figure: Historic and forecast sales for Sanorex (mazindol) in the seven
major markets, 2004 - 2018
- Figure: Obesity pipeline product performance against generic and currently
marketed products in the seven major markets, 2004 - 2018
- Figure: Datamonitor drug assessment summary for pipeline products in
development for obesity, 2009
- Figure: Contrave Phase III trial plan overview
- Figure: Contrave (bupropion and naltrexone) Phase III trial overview
- Figure: Contrave (bupropion and naltrexone) Phase III trial overview
- Figure: Contrave (bupropion and naltrexone) Phase III trial overview
- Figure: Contrave (naltrexone and bupropion) Phase IIb trial results
overview
- Figure: Contrave (naltrexone and bupropion) Phase II trial results overview
- Figure: Forecast sales for Contrave (bupropion and naltrexone) in the
seven major markets, 2008 - 2018
- Figure: Qnexa (phentermine and topiramate) Phase III trial plan overview
- Figure: Qnexa (phentermine and topiramate) EQUIP Phase III trial overview
- Figure: Qnexa (phentermine and topiramate) CONQUER Phase III trial overview
- Figure: Qnexa (phentermine and topiramate) EQUATE Phase III trial overview
- Figure: Qnexa (phentermine and topiramate) Phase II trial overview
- Figure: Forecast sales for Qnexa (phentermine and topiramate) in the seven
major markets , 2008 - 2018
- Figure: Lorcaserin trial plan overview
- Figure: Lorcaserin Phase III BLOOM trial overview
- Figure: Lorcaserin Phase III BLOSSOM trial overview
- Figure: Lorcaserin Phase III BLOOM-DM trial overview
- Figure: Forecast sales for lorcaserin in the seven major markets, 2008 -
2018
- Figure: Cetilistat monotherapy Phase III trial overview
- Figure: Other late-stage cetilistat trial plans
- Figure: Cetilistat Phase II trial in obese adults
- Figure: Cetilistat Phase II trial in obese adults with diabetes
- Figure: Forecast sales for cetilistat in the seven major markets,, 2008 -
2018
- Figure: Obesity pipeline by phase of development, 2006 - 09
- Figure: Obesity pipeline by activity status, 2006 - 09
|
Related Report
|
View Cart
